Medtronic Ardian Luxembourg S.a.r.l.

Covidien LP

Medtronic Vascular, Inc.

Medtronic Adrian Luxembourg S.a.r.l.

Carol M Sullivan

Ayala Hezi-Yamit

Susan Edwards

Christopher W Storment

Stefan Stoyanov Tunev

Rudy Beasley

Michele Lee Silver

Lori Garcia

Joseph A Traina

Gerald N Hodgkinson

Neil Chand Barman

Dwayne S Yamasaki

Joseph Traina

Daniel A Schulz-Jander

Terry Morgan

Brian Graham

Beth Sersen

Justin Peterson

Robert Melder

Ryan Bienvenu

Michael Harms

The present disclosure relates to medical devices, and methods for producing and using the devices. In embodiments, the medical device may be a buttress including a porous substrate possessing a therapeutic layer of a chemotherapeutic agent and optional excipient(s) thereon. By varying the form of chemotherapeutic agents and excipients, the medical devices may be used to treat both the area to which the medical device is attached as well as tissue at a distance therefrom.

Drug eluting medical device

Methods for treating and managing pain in a patient with therapeutic neuromodulation and associated systems and methods are disclosed herein. Chronic or debilitating pain can be associated, for example, with a disease or condition of the abdominal or reproductive viscera. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a target blood vessel of a diseased or damaged organ of a patient experiencing pain. Targeted sympathetic nerve activity can be modulated at least along afferent pathways which can improve a measurable parameter associated with the pain of the patient The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

Neuromodulation and associated systems and methods for the management of pain

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers. One aspect includes a comparison of baseline and post-modulation levels of one or more biomarkers in bodily fluid that have each been collected from a human subject at a relevant time, and that may be used to assess the neuromodulation efficacy. The post-neuromodulation levels for the one or more biomarkers may be collected from the human subject within about 5 minutes to about 14 days post-neuromodulation.

Monitoring of neuromodulation using biomarkers

Provided herein are methods, devices and compositions for assessing neuromodulation efficacy based on changes in the level of one or more biomarkers in plasma or urine collected from a human subject following a renal neuromodulation procedure.

Methods for assessing efficacy of renal neuromodulation and associated systems and devices

Provided herein are methods, systems, and devices for increasing heat shock protein expression and treating conditions for which increased heat shock protein expression is expected to be beneficial using thermal ablation.

Methods and devices for localized disease treatment by ablation

A stent includes a hollow wire formed into a stent pattern. The hollow wire includes an outer member, a lumen extending longitudinally within the hollow wire, at least one opening extending from an outer surface of the outer member to the lumen, and a surface area component within the hollow wire. The surface area component increases the amount of surface area available for tissue in-growth within the hollow wire. More than one surface area component may be utilized. Each surface area component may be disposed within the lumen or the at least one opening of the hollow wire. A pharmacologically or biologically active agent may be disposed within the lumen.

Drug-filled stents to prevent vessel micro-injuries and methods of manufacture thereof

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on changes in the level or activity of one or more target biomarkers.

Devices and associated methods for monitoring of neuromodulation using biomarkers

Provided herein are methods, systems, and devices for increasing IL-10 expression, inhibiting inflammation, and treating inflammatory conditions using thermal ablation.

Methods and devices for localized inhibition of inflammation by ablation

Provided herein are methods, devices, compositions, and kits for monitoring neuromodulation efficacy based on detecting changes in the level or activity of one or more target biomarkers associated with neuromodulation, as well as methods and processes of performing neuromodulation that incorporate monitoring of neuromodulation efficacy based on changes in level or activity of one or more target biomarkers.

Devices and methods for therapeutic photodynamic modulation of neural function in a human. One embodiment of a method in accordance with the technology includes administering a photosensitizer to a human, wherein the photosensitizer preferentially accumulates at nerves proximate a blood vessel compared to non-neural tissue of the blood vessel. The method can further include irradiating the photosensitizer using a radiation emitter positioned within the human, wherein the radiation has a wavelength that causes the photosensitizer to react and alter at least a portion of the nerves thereby providing a therapeutic reduction in sympathetic neural activity. Several embodiments of the technology are useful for disrupting renal nerves, such as renal denervation, for treating hypertension, diabetes, congestive heart failure, and other indications.

Growing community of inventors

Santa Rosa, CA, United States of America

Carol M Sullivan